<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">While improvement of vaccines and vaccination policy remains the best strategy to control global yellow fever endemics and epidemics, it is anticipated that other yellow fever outbreaks will occur in the near future. Therefore, it is crucial to develop safe and highly efficacious antiviral strategies against YFV infection that can be used not only for treating infected patients, but also for the prophylactic treatment of individuals potentially exposed to YFV, since sufficient post-vaccination immunity requires at least a week to develop (
 <xref rid="bib9" ref-type="bibr">Douam et al., 2018</xref>; 
 <xref rid="bib10" ref-type="bibr">Gaucher et al., 2008</xref>; 
 <xref rid="bib31" ref-type="bibr">Querec et al., 2009</xref>). Moreover, a safe antiviral therapy would be invaluable for visitors to endemic/epidemic regions who cannot safely take the attenuated vaccine (e.g., seniors and immunocompromised individuals). Presently, there is no antiviral drug available for the treatment and/or prevention of yellow fever (
 <xref rid="bib2" ref-type="bibr">Beasley et al., 2015</xref>; 
 <xref rid="bib8" ref-type="bibr">Douam and Ploss, 2018</xref>; 
 <xref rid="bib16" ref-type="bibr">Julander, 2013</xref>).
</p>
